Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of B1344 in Healthy Subjects
NCT05655221Phase 1Unknown
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of b1344 in Nonalcoholic steatohepatitis (NASH) (7 cohorts), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoints: 12-lead electrocardiogram, Renal Ultrasonography and 4 more. Status: unknown.
02
Drugs
b1344
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05655221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655221.